Medication info

Kwangdong Metformin Citalopram Tablet 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›858.5mg / 1 tablet
Manufacturer / importer
Kwangdong Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet with '715' engraved on one side
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200316 · Approved 2022.01.19

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medication should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the starting dose is one tablet of this medication 50/500 mg twice daily. The dose may be increased to one tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Take This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately.

Ingredients

Manufacturer
Kwangdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in type 2 diabetes patients
View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be used when the patient has not previously received diabetes medication treatment or when blood sugar control is insufficient with monotherapy. It is also administered when improvement is difficult with either metformin or sitagliptin monotherapy or when switching from a combination therapy of both medications. It is used in cases where blood sugar is poorly controlled with metformin and sulfonylurea, in combination with sulfonylurea. Similarly, if there is no effect from metformin and thiazolidinedione or from insulin and metformin combination therapies, this medication is added to improve blood sugar control. Therefore, this medication is used effectively to control blood sugar in various treatment situations.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medication should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the starting dose is one tablet of this medication 50/500 mg twice daily. The dose may be increased to one tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Take This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately.

Precautions

This medication contains sitagliptin and metformin, used for diabetes treatment. When taking this medication, severe allergic reactions may occur, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or lips appear, stop taking the medication immediately and consult a doctor. Acute pancreatitis, a serious inflammation of the pancreas, may occur, so pay close attention to symptoms such as abdominal pain, vomiting, and severe abdominal discomfort and inform medical personnel immediately if symptoms occur. The metformin contained in this medication can cause lactic acidosis, a rare but serious metabolic disorder, in patients with decreased kidney function, so kidney function should be periodically checked and it should not be taken if kidney function is impaired. Particularly in cases of dehydration, severe infection, heart disease, before and after surgery, liver dysfunction, pregnancy, and breastfeeding, this medication should not be used or should be used with caution. Additionally, irregular meals, excessive exercise, and interactions with other medications can lead to hypoglycemia, so blood sugar levels should be monitored closely. During the use of this medication, side effects such as diarrhea, headache, upper respiratory infection, and hypoglycemia symptoms should be managed promptly. Drinking alcohol may increase the risk of lactic acidosis, so alcoholic beverages should be avoided during treatment. Discontinue this medication 48 hours prior to surgery and resume only after confirming that kidney function is normal post-surgery. Women who are pregnant or may become pregnant and nursing mothers should not take this medication, and safety has not been established for children and adolescents under 18 years of age. Elderly patients are at higher risk of decreased kidney function, so regular kidney function tests are necessary and maintaining doses below the maximum dose is advisable. In case of overdose, immediate treatment at a medical institution is required, and if necessary, blood dialysis may be used to eliminate the drug. It is important to have regular blood tests and kidney function tests during treatment, and to consult a doctor immediately if any abnormal symptoms occur.

Side effects

anaphylaxis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture and should be kept at room temperature between 1 and 30 degrees Celsius. Therefore, it should be stored away from excessively hot or cold places.

Appearance and packaging

Appearance

Pink oval film-coated tablet with '715' engraved on one side

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.